COVID-19: Information on ASPIRA LABS Operations

Click to Learn More
  • Home
  • Recent News and Upcoming Events

Recent News and Upcoming Events

Recent News


  • Aspira Women’s Health, Inc., to Present at Cantor Virtual Healthcare Conference

    For a pdf of this press release please click here AUSTIN, Texas — September 8, 2020 — Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President and Chief Executive Officer, and Robert…

  • Aspira Women’s Health Reports Second Quarter 2020 Financial Results

    Conference Call scheduled for today, August 13th at 4:30 p.m. ET For a pdf of this press release including consolidated balance sheets please click here AUSTIN, Texas — August 13, 2020 — Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second…

  • Aspira Women’s Health CEO Valerie Palmieri quoted in Forbes

    Valerie Palmieri, President and CEO of Aspira Women's Health, was quoted in an article on Forbes.com today, Wednesday, July 8, 2020. The article describes the gender gap which exists in healthcare today and the steps companies are taking to challenge the status quo through research, innovation, and disruptive technology. Read the full article here.

  • Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million

    For a pdf of this press release please click here AUSTIN, Texas, July 1, 2020 — Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares…

  • Aspira Women’s Health, Inc. Announces First Patient Enrolled in Prospective OVANex Study for Benign Pelvic Mass Monitoring

    For a pdf of this press release please click here AUSTIN, Texas — June 29, 2020 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management. The study will enroll over 1,000 women for assessing ovarian cancer…

Investor Relations